ICAM1 and diabetic kidney disease: Chen et al. (2021) demonstrated that chronic administration of silymarin down-regulates IL-6 and intercellular adhesion molecule-1 (ICAM-1) expressions and alleviates TGF-β/Smad and JAK2/STAT3/ SOCS1 pathways using an STZ-induced diabetic nephropathy model of rats with improvements in podoxin and nephrin levels [105].